27Sep/13

Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to … – Sacramento Bee

Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to
Sacramento Bee
In February 2011, Roche began a Phase 3 registration trial of subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in patients with non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) and submitted a line extension 

and more »

26Sep/13

How SHARKS could be the key to beating breast cancer: Scientists hope … – Daily Mail


Daily Mail

How SHARKS could be the key to beating breast cancer: Scientists hope
Daily Mail
It is hoped that antibodies found the giants of the deep will lead to the ‘the new Herceptin’. Hailed as the biggest development in breast cancer for at least 25 years when it was launched more than a decade ago, Herceptin treats an especially fast
Shark antibodies may aid breast cancer fightTelegraph.co.uk
Shark antibodies ‘may target breast cancer’BBC News
Breast Cancer: Sharks’ Antibodies Could Hold KeySky News
International Business Times –Business Standard
all 10 news articles »
26Sep/13

Antibodies Could Halt Alzheimer's And Dementia Onset, Improve Cognitive … – Medical Daily


Medical Daily

Antibodies Could Halt Alzheimer’s And Dementia Onset, Improve Cognitive
Medical Daily
Using mice for their experiments, researchers at the Washington University School of Medicine in St. Louis looked for antibodies that prevented cells from assisting in the accumulation process of tau. They identified three that worked particularly well
Newly identified antibodies effectively treat Alzheimer’s-like disease in miceScience Codex

all 3 news articles »

26Sep/13

Breast Cancer: UK Scientists Think Shark Antibodies Could Be Crucial To … – International Business Times


International Business Times

Breast Cancer: UK Scientists Think Shark Antibodies Could Be Crucial To
International Business Times
“IgNAR antibodies are interesting because they bind to targets, such as viruses or parasites, in a very different way to the antibodies found in humans,” Dooley said. “They can do this because their attachment region is very small and so can fit into

26Sep/13

Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to … – PR Newswire (press release)

Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to
PR Newswire (press release)
In February 2011, Roche began a Phase 3 registration trial of subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in patients with non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) and submitted a line extension 

and more »